Key Stats for Vertex Pharmaceuticals Stock
- Pre-Market Price change for Vertex Pharmaceuticals stock: 5%
- $VRTX Share Price as of Mar. 9: $461
- 52-Week High: $520
- $VRTX Stock Price Target: $538
Now Live: Discover how much upside your favorite stocks could have using TIKR’s new Valuation Model (It’s free)>>>
What Happened?
Vertex Pharmaceuticals (VRTX) stock is moving higher after the company reported positive Phase 3 trial results for povetacicept, its drug targeting IgA nephropathy — a progressive kidney disease that affects hundreds of thousands of patients with no approved disease-modifying treatments.
The results were strong.
The trial showed povetacicept reduced proteinuria by roughly 50% compared to placebo, with statistical significance.
Proteinuria is a key marker of kidney damage, and reducing it meaningfully is considered a strong signal for long-term outcomes.
The drug also showed a 62% resolution rate for hematuria and a 77% reduction in a key disease biomarker, Gd-IgA1, at 36 weeks.
The safety profile looked clean, except for slightly elevated upper respiratory tract infection on the drug arm.
Vertex plans to complete its biologics license application by the end of March, which is slightly ahead of its previously communicated timeline.
If approved, this would mark the company’s entry into kidney disease as a major new commercial franchise.
Analyst reaction has been positive.
- Wolfe Research kept its Outperform rating and $548 price target.
- BMO Capital reiterated Outperform and raised its target to $600.
- Cantor Fitzgerald raised its price target to $590, citing the renal franchise’s potential to eventually rival Vertex’s cystic fibrosis business in scale.
See analysts’ growth forecasts and price targets for Vertex Pharmaceuticals stock (It’s free!) >>>
What the Market Is Telling Us About Vertex Pharmaceuticals Stock
VRTX stock has long been seen as one of the most durable biotechs, built on its dominant position in cystic fibrosis.
But investors have been watching closely to see whether the company can grow beyond that. These kidney disease results are a meaningful answer to that question.
The IgAN market is substantial. Roughly 330,000 patients in the U.S. and Europe are affected, with over 1 million in Asia.
Vertex is not alone in the space — Vera Therapeutics has a PDUFA date of July 7 — but the depth of Pove’s efficacy data and its convenient once-monthly auto-injector format give it a credible shot at market leadership.
For investors, VRTX stock now looks like more than just a CF story.
With a strong balance sheet, $12.3 billion in cash, and a pipeline expanding into kidney disease, pain, and beyond, the long-term growth case is getting more compelling.
Estimate a company’s fair value instantly (Free with TIKR) >>>
How Much Upside Does Vertex Pharmaceuticals Stock Have From Here?
With TIKR’s new Valuation Model tool, you can estimate a stock’s potential share price in under a minute.
All it takes is three simple inputs:
- Revenue Growth
- Operating Margins
- Exit P/E Multiple
If you’re not sure what to enter, TIKR automatically fills in each input using analysts’ consensus estimates, giving you a quick, reliable starting point.
From there, TIKR calculates the potential share price and total returns under Bull, Base, and Bear scenarios so you can quickly see whether a stock looks undervalued or overvalued.
See a stock’s true value in under 60 seconds (Free with TIKR) >>>
Looking for New Opportunities?
- See what stocks billionaire investors are buying so you can follow the smart money.
- Analyze stocks in as little as 5 minutes with TIKR’s all-in-one, easy-to-use platform.
- The more rocks you overturn… the more opportunities you’ll uncover. Search 100K+ global stocks, global top investor holdings, and more with TIKR.
Disclaimer:
Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any stocks mentioned. Thank you for reading, and happy investing!
